Mashup Score:43
cibmtr.orgCIBMTR Working Committee Training and Leadership (CTL) Program - 2 weeks
Mashup Score:43
# bmtsm
Mashup Score:29
American Society of HematologyUsing 3 illustrative cases, Chaer et al discuss the options for the prevention and therapy of COVID-19 infection in patients with hematologic malignancies and...
-
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies [Aug 18, 2022] @FirasElChaer , Auletta, @ChemalyRoy @BloodJournal https://t.co/JIfU1A6USH #bmtsm #CARTcell #leusm #lymsm #mmsm #mpnsm https://t.co/JIfU1A6USH - view on twitter
Mashup Score:25
American Society of HematologyKey Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...
-
Impact of SPM Post-AutoSCT on MM. Incidence: 4%. SPM associated with worse PFS, but MM remains the primary cause of death in SPM patients @CIBMTR @szusmani @BKRagonMD @adsouza_md #mmsm #bmtsm https://t.co/NOX1N9cBlA - view on twitter
Mashup Score:22
American Society of HematologyKey Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...
-
Important @CIBMTR #myeloma study by Dr Ragon @szusmani et al: 4% #auto BMT recipients developed 2nd cancer at median ~3yr follow up; 2nd cancers associated w/⬇️PFS & OS; myeloma still main cause of death #mmsm #bmtsm https://t.co/CDrd86AkEL - view on twitter
Mashup Score:19
ScienceDirectRecent ASTCT guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and...
-
Demographics, motivations, and experiences of participants in transplantation or cellular therapy fellowships @RahulBanerjeeMD @BldCancerDoc @amarkelkar @TheodoraAnagno1 @hemedoc @mikinishitanimd @ASTCT_Journal @ASTCT #bmtsm #TcellRx #MedEd https://t.co/g1xm9eg8b1 - view on twitter
Mashup Score:16
ScienceDirectFor patients with newly diagnosed multiple myeloma (MM) undergoing high dose chemotherapy-autologous stem cell transplant (HDT-ASCT), hematopoietic...
-
The addition of daratumumab to induction with VRd (Dara-VRd) did not lead to any clinically significant differences in stem cell yield and number of collection days, provided patient received pre-emptive GCSF and plerixafor #mmsm #bmtsm @hamzahashmi87 https://t.co/tbmvqx0f1q - view on twitter
Mashup Score:15
ScienceDirectChimeric antigen receptor (CAR) T cell (CAR-T) therapy represents a revolutionary treatment for patients with relapsed/refractory hematologic...
-
RT @CARTTherapy: Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppr... https://t.co/wiXDHWuLId #CART #bmtsm #immunoth… - view on twitter
Mashup Score:14
cibmtr.orgCIBMTR Working Committee Training and Leadership (CTL) Program - 1 month
Mashup Score:14
Opportunities for Early Career Investigators We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators (ECI). As...
-
Nice to see this great opportunity for Early Career investigators in #bmtsm (ideally 3-7 years from fellowship) : @CIBMTR Working Committee Training and Leadership Program. Application https://t.co/TtwE4FcR8g @ASTCT #Tandem23 https://t.co/TtwE4FcR8g - view on twitter
Mashup Score:13
PubMedCase series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host...
-
Low dose ibrutinib plus itraconazole create a new promising option in #GVHD #BMTsm Link to the article: https://t.co/12iMi2LzZz https://t.co/12iMi2LzZz - view on twitter
Mashup Score:12
American Society of HematologyKey Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory large B-cell lymphomaDurable responses...
-
RT @CARTTherapy: 5-Year Follow-Up Supports Curative Potential of Axi-cel in Refractory LBCL (ZUMA-1) https://t.co/gxuBuw7ZRr #CART #bmtsm… - view on twitter
-
5-Year Follow-Up Supports Curative Potential of Axi-cel in Refractory LBCL (ZUMA-1) https://t.co/gxuBuw7ZRr #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CARTTherapy @CART_Therapy @BloodJournal @BloodAdvances - view on twitter
More coverage:
#bmtsm
#cart
#cartcell
#cartcells
#celltherapy
#crs
#gene
#genetherapy
#ican
#immunotherapy
#tcellrx
We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators...
Junior faculty apply for this great opportunity @CIBMTR Working Committee Training and Leadership (CTL) Program #bmtsm #CARTcells https://t.co/c10Z9xGB3q - view on twitter